Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer

BACKGROUND: Oral mucositis is a debilitating side effect of cancer treatment for which there is not much successful treatments at yet. We evaluated the effectiveness of topical morphine compared with a routine mouthwash in managing cancer treatment-induced mucositis. MATERIALS AND METHODS: Thirty he...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarvizadeh, Mostafa, Hemati, Simin, Meidani, Mohsen, Ashouri, Moghtada, Roayaei, Mahnaz, Shahsanai, Armindokht
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358035/
https://www.ncbi.nlm.nih.gov/pubmed/25789270
http://dx.doi.org/10.4103/2277-9175.151254
_version_ 1782361233978032128
author Sarvizadeh, Mostafa
Hemati, Simin
Meidani, Mohsen
Ashouri, Moghtada
Roayaei, Mahnaz
Shahsanai, Armindokht
author_facet Sarvizadeh, Mostafa
Hemati, Simin
Meidani, Mohsen
Ashouri, Moghtada
Roayaei, Mahnaz
Shahsanai, Armindokht
author_sort Sarvizadeh, Mostafa
collection PubMed
description BACKGROUND: Oral mucositis is a debilitating side effect of cancer treatment for which there is not much successful treatments at yet. We evaluated the effectiveness of topical morphine compared with a routine mouthwash in managing cancer treatment-induced mucositis. MATERIALS AND METHODS: Thirty head and neck cancer patients with severe mucositis (World Health Organization Grade III or IV) were randomized into the morphine and magic mouthwash groups. Patients received morphine sulfate 2% or magic solution (contained magnesium aluminum hydroxide, viscous lidocaine, and diphenhydramine), 10 ml for every 3 h, six times a day, for 6 days. Both groups received same dietary and oral hygiene instructions and care. Mucositis was graded at baseline and every 3 days after treatment. Patients’ satisfaction and drug effect maintenance were also evaluated. RESULTS: Twenty-eight patients (mean age of 49.5 ± 13.2 years, 63.3% female) completed the trial; 15 in the morphine group and 13 in the magic group. There was a decrease in mucositis severity in both of the morphine (P < 0.001) and magic (P = 0.049) groups. However, at the 6(th) day, more reduction was observed in mucositis severity in the morphine compared with magic group (P = 0.045). Drug effect maintenance was similar between the two groups, but patients in the morphine group were more satisfied by their treatments than those in the magic group (P = 0.008). CONCLUSIONS: Topical morphine is more effective and more satisfactory to patients than the magic mouthwash in reducing severity of cancer treatment-induced oral mucositis. More studies with larger sample size and longer follow-up are required in this regard.
format Online
Article
Text
id pubmed-4358035
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-43580352015-03-18 Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer Sarvizadeh, Mostafa Hemati, Simin Meidani, Mohsen Ashouri, Moghtada Roayaei, Mahnaz Shahsanai, Armindokht Adv Biomed Res Original Article BACKGROUND: Oral mucositis is a debilitating side effect of cancer treatment for which there is not much successful treatments at yet. We evaluated the effectiveness of topical morphine compared with a routine mouthwash in managing cancer treatment-induced mucositis. MATERIALS AND METHODS: Thirty head and neck cancer patients with severe mucositis (World Health Organization Grade III or IV) were randomized into the morphine and magic mouthwash groups. Patients received morphine sulfate 2% or magic solution (contained magnesium aluminum hydroxide, viscous lidocaine, and diphenhydramine), 10 ml for every 3 h, six times a day, for 6 days. Both groups received same dietary and oral hygiene instructions and care. Mucositis was graded at baseline and every 3 days after treatment. Patients’ satisfaction and drug effect maintenance were also evaluated. RESULTS: Twenty-eight patients (mean age of 49.5 ± 13.2 years, 63.3% female) completed the trial; 15 in the morphine group and 13 in the magic group. There was a decrease in mucositis severity in both of the morphine (P < 0.001) and magic (P = 0.049) groups. However, at the 6(th) day, more reduction was observed in mucositis severity in the morphine compared with magic group (P = 0.045). Drug effect maintenance was similar between the two groups, but patients in the morphine group were more satisfied by their treatments than those in the magic group (P = 0.008). CONCLUSIONS: Topical morphine is more effective and more satisfactory to patients than the magic mouthwash in reducing severity of cancer treatment-induced oral mucositis. More studies with larger sample size and longer follow-up are required in this regard. Medknow Publications & Media Pvt Ltd 2015-02-11 /pmc/articles/PMC4358035/ /pubmed/25789270 http://dx.doi.org/10.4103/2277-9175.151254 Text en Copyright: © 2015 Sarvizadeh. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Sarvizadeh, Mostafa
Hemati, Simin
Meidani, Mohsen
Ashouri, Moghtada
Roayaei, Mahnaz
Shahsanai, Armindokht
Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title_full Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title_fullStr Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title_full_unstemmed Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title_short Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
title_sort morphine mouthwash for the management of oral mucositis in patients with head and neck cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4358035/
https://www.ncbi.nlm.nih.gov/pubmed/25789270
http://dx.doi.org/10.4103/2277-9175.151254
work_keys_str_mv AT sarvizadehmostafa morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer
AT hematisimin morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer
AT meidanimohsen morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer
AT ashourimoghtada morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer
AT roayaeimahnaz morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer
AT shahsanaiarmindokht morphinemouthwashforthemanagementoforalmucositisinpatientswithheadandneckcancer